quinapril 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
angiotensin-converting enzyme inhibitors 2340 85441-61-8

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • quinapril
  • ectren
  • koretic
  • quinapril hydrochloride
  • quinapril HCl
A tetrahydroisoquinoline derivative and ANGIOTENSIN CONVERTING ENZYME inhibitor that is used in the treatment of HYPERTENSION and HEART FAILURE.
  • Molecular weight: 438.52
  • Formula: C25H30N2O5
  • CLOGP: 1.74
  • LIPINSKI: 0
  • HAC: 7
  • HDO: 2
  • TPSA: 95.94
  • ALOGS: -4.71
  • ROTB: 10
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
15 mg O
15 mg P

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Bocci G, Oprea TI, Benet LZ
S (Water solubility) 0.00 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 3.10 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 2.61 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 50 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
azlogd74 LogD at pH 7.4 0.509 High 1
caco2-efflux Caco-2 efflux ratio (BA/AB) 6.397 High 1
caco2-intrinsic-papp Caco-2 intrinsic apparent permeability 3.451 10^-6 cm/s High 1
dh-clint Dog hepatocyte intrinsic clearance 14.125 uL/min/10^6 cells High 1
dppb Dog plasma protein binding (% unbound) 4.100 % High 1
fcs-ppb Fetal calf serum protein binding (% unbound) 6.180 % High 1
herg hERG pIC50 4.284 pIC50 High 1
hh-clint Human hepatocyte intrinsic clearance 38.019 uL/min/10^6 cells High 1
hlm-clint Human liver microsomal intrinsic clearance 41.783 uL/min/mg protein High 1
hppb Human plasma protein binding (% unbound) 4.990 % High 1
kinase-safety-class ACVR2A,ACVR2B,AXL,BRAF,BTK,CAMK2D,CDK5,CDK9,DYRK1B,EIF2AK3,EPHB4,ERBB2,GRK2,ITK,MAP2K6,MAP3K7,MAPK7,MAPKAPK2,NTRK2,PDK1,PDK2,PDK4,PIK3CB,PRKDC,SYK,TEK,TGFBR1 27
kinase-selectivity-class AXL,BRAF,EPHB4,GRK2,MAP2K6,PDK4 6
mdck-mdr1-bcrp-efflux MDCK-MDR1-BCRP efflux ratio 2.393 Moderate 0.69
mdck-mdr1-efflux MDCK-MDR1 efflux ratio 1.862 High 1
mh-clint Mouse hepatocyte intrinsic clearance 51.642 High 1
mppb Mouse plasma protein binding (% unbound) 3.890 High 1
nih-mdck-mdr1-efflux NIH MDCK-MDR1 efflux ratio 9.268 High 1
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pld-class Phospholipidosis risk class (1 = positive, 0 = negative) 0 Moderate 0.66
pppb Pig plasma protein binding (% unbound) 7.170 % High 1
rat-kpuu-brain Rat brain Kpuu 0.008 % Moderate 0.69
rh-clint Rat hepatocyte intrinsic clearance 115.080 uL/min/10^6 cells High 1
rh-fuinc Rat hepatocyte fraction unbound in incubation 68.980 % High 1
rppb Rat plasma protein binding (% unbound) 3.190 % High 1
solubility-dd Solubility at pH 7.4 in DMSO 931.108 uM High 1

Approvals:

DateAgencyCompanyOrphan
Nov. 19, 1991 FDA PFIZER PHARMS

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Creatinine renal clearance decreased 1370.63 22.09 350 12214 18549 90597334
Sedation complication 1363.42 22.09 341 12223 16603 90599280
Orthostatic hypotension 1356.97 22.09 412 12152 41415 90574468
Sedation 1229.37 22.09 395 12169 47776 90568107
Blood calcium decreased 1208.31 22.09 350 12214 29832 90586051
Cognitive disorder 1155.80 22.09 413 12151 68994 90546889
Balance disorder 1034.78 22.09 417 12147 96663 90519220
Depressed level of consciousness 913.12 22.09 352 12212 72432 90543451
Constipation 641.26 22.09 427 12137 279968 90335915
Hypotension 588.31 22.09 429 12135 324968 90290915
Fall 578.84 22.09 499 12065 481311 90134572
Toxicity to various agents 480.35 22.09 362 12202 287484 90328399
Mobility decreased 476.18 22.09 341 12223 250393 90365490
Creatinine renal clearance increased 171.52 22.09 47 12517 3234 90612649
Renal function test abnormal 154.73 22.09 52 12512 7139 90608744
Pain 151.30 22.09 386 12178 995955 89619928
Multiple drug therapy 144.17 22.09 49 12515 6960 90608923
Heart sounds 117.05 22.09 28 12536 1116 90614767
Prolonged expiration 114.43 22.09 28 12536 1229 90614654
Depressive symptom 78.44 22.09 29 12535 5256 90610627
Respiration abnormal 66.92 22.09 29 12535 7934 90607949
Hypertensive emergency 63.83 22.09 20 12544 2197 90613686
Appetite disorder 63.11 22.09 29 12535 9104 90606779
Cardiac failure congestive 48.52 22.09 64 12500 98630 90517253
Rales 45.52 22.09 28 12536 15799 90600084
Flank pain 45.33 22.09 30 12534 19192 90596691
Angina pectoris 39.48 22.09 37 12527 39123 90576760
Myocardial infarction 39.20 22.09 60 12504 105912 90509971
Drug ineffective 38.15 22.09 85 12479 1384213 89231670
Drug abuse 36.82 22.09 51 12513 82296 90533587
Arthropathy 34.27 22.09 5 12559 366237 90249646
Synovitis 32.04 22.09 4 12560 329748 90286135
Rash 31 22.09 39 12525 796061 89819822
Bladder disorder 30.83 22.09 19 12545 10753 90605130
Dementia 28.89 22.09 25 12539 23836 90592047
Hepatic enzyme increased 27.42 22.09 8 12556 360728 90255155
Glossodynia 26.63 22.09 6 12558 321773 90294110
Therapeutic product effect decreased 25.47 22.09 4 12560 277567 90338316
Alopecia 25.33 22.09 19 12545 495052 90120831
Hypersensitivity 25.18 22.09 16 12548 454661 90161222
Discomfort 25.07 22.09 4 12560 274331 90341552
General physical health deterioration 25.00 22.09 9 12555 355106 90260777
Decreased activity 24.86 22.09 15 12549 8177 90607706
Drug interaction 23.57 22.09 88 12476 276365 90339518
Cerebrovascular accident 22.93 22.09 52 12512 123481 90492402
Exposure during pregnancy 22.89 22.09 3 12561 238407 90377476
Overdose 22.49 22.09 60 12504 157649 90458234
Impaired healing 22.36 22.09 3 12561 234196 90381687
Productive cough 22.22 22.09 39 12525 77024 90538859

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Blood mercury abnormal 139.56 18.51 25 5226 257 42615827
Low density lipoprotein decreased 101.40 18.51 25 5226 1279 42614805
Expired product administered 92.66 18.51 30 5221 4133 42611951
Hepatic neoplasm 88.54 18.51 25 5226 2166 42613918
5-hydroxyindolacetic acid in urine increased 87.83 18.51 16 5235 182 42615902
Cardiac failure congestive 71.48 18.51 69 5182 85533 42530551
Head titubation 68.47 18.51 15 5236 454 42615630
Neoplasm 66.12 18.51 26 5225 6279 42609805
Glycosylated haemoglobin increased 56.83 18.51 29 5222 12895 42603189
Myocardial infarction 56.77 18.51 73 5178 123936 42492148
5-hydroxyindolacetic acid increased 48.95 18.51 9 5242 108 42615976
Cogwheel rigidity 48.45 18.51 15 5236 1786 42614298
Blood glucose increased 48.01 18.51 52 5199 73647 42542437
Arteriosclerosis coronary artery 46.85 18.51 29 5222 18648 42597436
Blood follicle stimulating hormone increased 43.12 18.51 9 5242 215 42615869
Hypertensive emergency 40.00 18.51 12 5239 1285 42614799
Blood potassium decreased 39.69 18.51 27 5224 20357 42595727
Fibrous histiocytoma 38.97 18.51 9 5242 347 42615737
Angioedema 36.83 18.51 35 5216 42442 42573642
Haematocrit decreased 36.60 18.51 32 5219 34876 42581208
Renal phospholipidosis 34.31 18.51 7 5244 149 42615935
Sedation complication 34.01 18.51 13 5238 2906 42613178
Gamma-glutamyltransferase increased 32.49 18.51 29 5222 32468 42583616
Blood pressure systolic increased 30.04 18.51 26 5225 27942 42588142
Acute myocardial infarction 29.36 18.51 36 5215 58129 42557955
Red blood cell count decreased 28.43 18.51 27 5224 32688 42583396
Urticaria 28.34 18.51 40 5211 73996 42542088
Coronary artery disease 28.33 18.51 34 5217 53686 42562398
Extrapyramidal disorder 25.62 18.51 19 5232 16393 42599691
Syncope 24.62 18.51 44 5207 99362 42516722
Rhabdomyolysis 23.92 18.51 38 5213 77981 42538103
Pseudohyponatraemia 23.40 18.51 5 5246 134 42615950
Bronchomalacia 22.46 18.51 5 5246 163 42615921
Cardiopulmonary failure 22.01 18.51 11 5240 4672 42611412
Anticholinergic syndrome 21.88 18.51 8 5243 1581 42614503
Paralysis 20.44 18.51 12 5239 7008 42609076
Aspartate aminotransferase increased 20.19 18.51 35 5216 77128 42538956

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Sedation complication 1387.55 18.53 362 16002 19493 110553442
Creatinine renal clearance decreased 1330.08 18.53 357 16007 21458 110551477
Orthostatic hypotension 1169.39 18.53 419 15945 65830 110507105
Blood calcium decreased 1167.53 18.53 360 16004 35485 110537450
Sedation 1081.97 18.53 401 15963 69282 110503653
Cognitive disorder 1062.84 18.53 421 15943 87090 110485845
Balance disorder 956.03 18.53 424 15940 116136 110456799
Depressed level of consciousness 767.56 18.53 360 16004 111918 110461017
Constipation 530.13 18.53 431 15933 357355 110215580
Mobility decreased 525.52 18.53 364 16000 237058 110335877
Fall 493.00 18.53 521 15843 602961 109969974
Hypotension 461.18 18.53 471 15893 523378 110049557
Toxicity to various agents 337.73 18.53 384 15980 480171 110092764
Pain 170.29 18.53 410 15954 954545 109618390
Creatinine renal clearance increased 163.84 18.53 47 16317 3578 110569357
Renal function test abnormal 140.28 18.53 52 16312 8894 110564041
Blood mercury abnormal 134.95 18.53 25 16339 257 110572678
Multiple drug therapy 134.60 18.53 49 16315 7965 110564970
Heart sounds 115.25 18.53 28 16336 1115 110571820
Cardiac failure congestive 107.74 18.53 122 16242 150878 110422057
Prolonged expiration 106.75 18.53 28 16336 1524 110571411
Hypertensive emergency 97.72 18.53 31 16333 3320 110569615
Low density lipoprotein decreased 94.67 18.53 25 16339 1397 110571538
Myocardial infarction 87.37 18.53 124 16240 191959 110380976
5-hydroxyindolacetic acid in urine increased 84.72 18.53 16 16348 184 110572751
Expired product administered 73.51 18.53 32 16332 8288 110564647
Hepatic neoplasm 70.02 18.53 25 16339 3842 110569093
Depressive symptom 63.57 18.53 29 16335 8385 110564550
Respiration abnormal 62.34 18.53 30 16334 9779 110563156
Appetite disorder 59.44 18.53 29 16335 9740 110563195
5-hydroxyindolacetic acid increased 45.95 18.53 9 16355 127 110572808
Neoplasm 44.75 18.53 25 16339 11062 110561873
Angina pectoris 43.81 18.53 50 16314 62245 110510690
Glycosylated haemoglobin increased 42.38 18.53 32 16332 23587 110549348
Flank pain 40.76 18.53 31 16333 23099 110549836
Coronary artery disease 39.74 18.53 51 16313 71639 110501296
Arteriosclerosis coronary artery 38.50 18.53 31 16333 25087 110547848
Bladder disorder 36.67 18.53 22 16342 11115 110561820
Blood follicle stimulating hormone increased 36.04 18.53 9 16355 402 110572533
Rales 34.70 18.53 29 16335 24710 110548225
Neutropenia 34.02 18.53 7 16357 374613 110198322
Drug ineffective 33.19 18.53 115 16249 1520425 109052510
General physical health deterioration 32.83 18.53 11 16353 425284 110147651
Blood glucose increased 32.58 18.53 65 16299 132431 110440504
Off label use 32.37 18.53 114 16250 1500071 109072864
Angioedema 31.35 18.53 54 16310 98446 110474489
Fibrous histiocytoma 29.68 18.53 9 16355 830 110572105
Head titubation 29.28 18.53 10 16354 1347 110571588
Cerebrovascular accident 27.98 18.53 74 16290 181210 110391725
Synovitis 27.33 18.53 4 16360 274088 110298847
Arthropathy 26.88 18.53 5 16359 287517 110285418
Renal phospholipidosis 26.51 18.53 7 16357 391 110572544
Acute myocardial infarction 25.45 18.53 45 16319 83732 110489203
Red blood cell count decreased 24.83 18.53 39 16325 65884 110507051
Blood potassium decreased 24.65 18.53 35 16329 54079 110518856
Condition aggravated 24.16 18.53 45 16319 734791 109838144
Rash 23.84 18.53 54 16310 820910 109752025
Dementia 23.25 18.53 26 16338 31647 110541288
Febrile neutropenia 23.06 18.53 9 16355 316758 110256177
Infection 22.23 18.53 13 16351 362187 110210748
Haematocrit decreased 22.03 18.53 37 16327 66080 110506855
Depressed mood 21.56 18.53 35 16329 60774 110512161
Allergy to arthropod bite 21.17 18.53 6 16358 437 110572498
Systemic lupus erythematosus 20.65 18.53 6 16358 254332 110318603
Pseudohyponatraemia 20.48 18.53 5 16359 203 110572732
Decreased activity 19.98 18.53 15 16349 10959 110561976
Cogwheel rigidity 19.61 18.53 10 16354 3688 110569247
Hepatic enzyme increased 19.02 18.53 12 16352 320880 110252055

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC C09AA06 CARDIOVASCULAR SYSTEM
AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM
ACE INHIBITORS, PLAIN
ACE inhibitors, plain
ATC C09BA06 CARDIOVASCULAR SYSTEM
AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM
ACE INHIBITORS, COMBINATIONS
ACE inhibitors and diuretics
FDA MoA N0000000181 Angiotensin-converting Enzyme Inhibitors
FDA EPC N0000175562 Angiotensin Converting Enzyme Inhibitor
MeSH PA D000806 Angiotensin-Converting Enzyme Inhibitors
MeSH PA D000959 Antihypertensive Agents
MeSH PA D002317 Cardiovascular Agents
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D011480 Protease Inhibitors
CHEBI has role CHEBI:35457 EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
CHEBI has role CHEBI:35526 hypoglycemic agent
CHEBI has role CHEBI:35674 antihypertensive agent
CHEBI has role CHEBI:50266 prodrug
CHEBI has role CHEBI:35554 cardiovascular drug
CHEBI has role CHEBI:35620 vasodilator agent

Related Drugs by ATC class:

C09AA ACE inhibitors, plain 15 drugs
benazeprilcaptoprilcilazaprildelaprilenalaprilfosinoprilimidaprillisinoprilmoexiprilperindoprilramiprilspirapril show all 15 →
C09BA ACE inhibitors and diuretics 11 drugs
benazeprilcaptoprilcilazaprildelaprilenalaprilfosinoprillisinoprilmoexiprilperindoprilramiprilzofenopril

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Hypertensive disorder indication 38341003 DOID:10763
Chronic heart failure indication 48447003
Atrial fibrillation off-label use 49436004 DOID:0060224
Diabetic renal disease off-label use 127013003
Acute scleroderma renal crisis off-label use 236503001
Diastolic heart failure off-label use 418304008 DOID:9775
Nondiabetic Proteinuric Nephropathy off-label use
Anuria contraindication 2472002 DOID:2983
Hypercholesterolemia contraindication 13644009
Hyperkalemia contraindication 14140009
Secondary angle-closure glaucoma contraindication 21571006
Hypovolemia contraindication 28560003
Acute cerebrovascular insufficiency contraindication 29322000
Dehydration contraindication 34095006
Hyperuricemia contraindication 35885006 DOID:1920
Immunosuppression contraindication 38013005
Angioedema contraindication 41291007 DOID:1558
Hypokalemia contraindication 43339004
Low blood pressure contraindication 45007003
Systemic lupus erythematosus contraindication 55464009 DOID:9074
Sympathectomy contraindication 57071006
Hypercalcemia contraindication 66931009 DOID:12678
Hyperparathyroidism contraindication 66999008 DOID:13543
Hypochloremic alkalosis contraindication 70134007
Hepatic coma contraindication 72836002 DOID:12550
Diabetes mellitus contraindication 73211009 DOID:9351
Hereditary angioneurotic edema contraindication 82966003 DOID:14735
Hyponatremia contraindication 89627008
Gout contraindication 90560007 DOID:13189
Kidney disease contraindication 90708001 DOID:557
Disorder of connective tissue contraindication 105969002 DOID:65
Hypomagnesemia contraindication 190855004
Acute pancreatitis contraindication 197456007 DOID:2913
Disease of liver contraindication 235856003 DOID:409
Neonatal hyperbilirubinemia contraindication 281610001
Pregnancy, function contraindication 289908002
Renal artery stenosis contraindication 302233006
Neutropenic disorder contraindication 303011007 DOID:1227
Bone marrow depression contraindication 307762000
Myocardial ischemia contraindication 414795007 DOID:3393
Azotemia contraindication 445009001
Hemodialysis with High-Flux Membrane contraindication




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 2.96 acidic
pKa2 5.72 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Angiotensin-converting enzyme Enzyme INHIBITOR IC50 8.08 CHEMBL CHEMBL
Angiotensin-converting enzyme Enzyme IC50 5.40 DRUG MATRIX

External reference:

IDSource
4020549 VUID
N0000148256 NUI
D00459 KEGG_DRUG
82586-55-8 SECONDARY_CAS_RN
4020379 VANDF
4020549 VANDF
C0072857 UMLSCUI
CHEBI:8713 CHEBI
CHEMBL1592 ChEMBL_ID
CHEMBL1201011 ChEMBL_ID
D000077583 MESH_DESCRIPTOR_UI
DB00881 DRUGBANK_ID
6350 IUPHAR_LIGAND_ID
5780 INN_ID
RJ84Y44811 UNII
54892 PUBCHEM_CID
DB14217 DRUGBANK_ID
1546359 RXNORM
5401 MMSL
63990 MMSL
d00365 MMSL
003612 NDDF
003613 NDDF
108578004 SNOMEDCT_US
386874003 SNOMEDCT_US
386875002 SNOMEDCT_US
C0072858 UMLSCUI
CHEMBL1733 ChEMBL_ID
82768-85-2 SECONDARY_CAS_RN
107994 PUBCHEM_CID
6352 IUPHAR_LIGAND_ID
6356 INN_ID
C054501 MESH_SUPPLEMENTAL_RECORD_UI
34SSX5LDE5 UNII
CHEBI:140296 CHEBI
34SSX5LDE5 INXIGHT DRUGS
RJ84Y44811 INXIGHT DRUGS

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Quinapril HUMAN PRESCRIPTION DRUG LABEL 1 21695-393 TABLET 5 mg ORAL ANDA 24 sections
Quinapril HUMAN PRESCRIPTION DRUG LABEL 1 21695-394 TABLET 10 mg ORAL ANDA 24 sections
Quinapril HUMAN PRESCRIPTION DRUG LABEL 1 31722-267 TABLET 5 mg ORAL ANDA 22 sections
Quinapril HUMAN PRESCRIPTION DRUG LABEL 1 31722-268 TABLET 10 mg ORAL ANDA 22 sections
Quinapril HUMAN PRESCRIPTION DRUG LABEL 1 31722-269 TABLET 20 mg ORAL ANDA 22 sections
Quinapril HUMAN PRESCRIPTION DRUG LABEL 1 31722-270 TABLET 40 mg ORAL ANDA 22 sections
Quinapril Hydrochloride and Hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 2 31722-374 TABLET 10 mg ORAL ANDA 23 sections
Quinapril Hydrochloride and Hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 2 31722-375 TABLET 20 mg ORAL ANDA 23 sections
Quinapril Hydrochloride and Hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 2 31722-376 TABLET 20 mg ORAL ANDA 23 sections
Quinapril HCL and Hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 2 43386-710 TABLET 10 mg ORAL ANDA 12 sections
Quinapril HCL and Hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 2 43386-711 TABLET 20 mg ORAL ANDA 12 sections
Quinapril HCL and Hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 2 43386-712 TABLET 20 mg ORAL ANDA 12 sections
QUINAPRIL HUMAN PRESCRIPTION DRUG LABEL 1 43547-410 TABLET 5 mg ORAL ANDA 13 sections
QUINAPRIL HUMAN PRESCRIPTION DRUG LABEL 1 43547-411 TABLET 10 mg ORAL ANDA 13 sections
QUINAPRIL HUMAN PRESCRIPTION DRUG LABEL 1 43547-412 TABLET 20 mg ORAL ANDA 13 sections
QUINAPRIL HUMAN PRESCRIPTION DRUG LABEL 1 43547-413 TABLET 40 mg ORAL ANDA 13 sections
Quinapril Human Prescription Drug Label 1 50090-2116 TABLET, FILM COATED 20 mg ORAL ANDA 20 sections
Quinapril Human Prescription Drug Label 1 50090-2117 TABLET, FILM COATED 40 mg ORAL ANDA 20 sections
Quinapril HUMAN PRESCRIPTION DRUG LABEL 1 50090-4649 TABLET 40 mg ORAL ANDA 13 sections
Quinapril HUMAN PRESCRIPTION DRUG LABEL 1 51655-737 TABLET 40 mg ORAL ANDA 12 sections
Quinapril Hydrochloride and Hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 2 54868-1802 TABLET, FILM COATED 10 mg ORAL ANDA 12 sections
Quinapril Hydrochloride and Hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 2 54868-2847 TABLET, FILM COATED 20 nmol ORAL ANDA 12 sections
Quinapril HUMAN PRESCRIPTION DRUG LABEL 1 54868-5241 TABLET, FILM COATED 20 mg ORAL ANDA 12 sections
Quinapril HUMAN PRESCRIPTION DRUG LABEL 1 54868-5245 TABLET, FILM COATED 10 mg ORAL ANDA 12 sections
Quinapril HUMAN PRESCRIPTION DRUG LABEL 1 54868-5246 TABLET, FILM COATED 40 mg ORAL ANDA 12 sections
Quinapril HUMAN PRESCRIPTION DRUG LABEL 1 54868-5279 TABLET, FILM COATED 5 mg ORAL ANDA 12 sections
Quinapril Hydrochloride and Hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 2 54868-5475 TABLET, FILM COATED 20 mg ORAL ANDA 12 sections
Quinapril HUMAN PRESCRIPTION DRUG LABEL 1 55111-621 TABLET 5 mg ORAL ANDA 19 sections
Quinapril HUMAN PRESCRIPTION DRUG LABEL 1 55111-622 TABLET 10 mg ORAL ANDA 19 sections
Quinapril HUMAN PRESCRIPTION DRUG LABEL 1 55111-623 TABLET 20 mg ORAL ANDA 19 sections